Value of Analysing Under-utilised Leftover Tissue (VauLT)

ConditionOncology
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRoyal Marsden NHS Foundation Trust

About this trial

Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.

Eligibility criteria

Qualifiers

Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery.

Tissues for Research consent has been provided.

Patient age >18yo.

Minimum of 1 gram of residual tumour remaining in leftover surgical tissue

Disqualifiers

Advanced Practitioner in histological dissection deems tumour sample to be inadequate.

Leftover surgical tumour tissue greater than 20kg.

Trial design

Treatments tested in this trial

  • Leftover surgical tissue homogenization

Treatment groups

No treatment groups listed

Sponsors and collaborators

Royal Marsden NHS Foundation Trust

Lead sponsor

Ventana Medical Systems

Collaborator